Get started

Zomedica

IMPORTANT day for CTRM Castor Maritime has to close above 1$Important day!! 10/10 days that we have to close above 1$ to keep it at NasDaq. But...! Only buy at the end of the day to let it run to our target. The closure above 1.00$ is the most important. What happens throughout the day is unimportant in my opinion! I have taken a close look at this company. In my view, the rise will continue uninterrupted unless the entire market has a dip day that pulls CTRM down with it, but that is a healthy correction. The company continues to purchase ships, which will be very good for their revenue stream in the long run. However, the earnings that are released on 3/3 may disappoint somewhat, because of the purchases the cash may be lower or the debt may be higher. Depending on how they bought it. There is enough cash, but long-term loans are also possible to finance these purchases. I am very positive about CTRM so i will keep them for the long run. From 1 dollar a lot is possible in a positive way. For example, look at the increase in Fuel Cell stock (FCEL), 1000% within 6 months. I see something like this possible with CTRM.
NASDAQ:CTRMLong
by Amsterdamn
22
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken